Latest Furiex Pharmaceuticals (FURX) Headlines Furiex

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Furiex Pharmaceuticals (FURX) Headlines

Furiex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Tue Mar 11, 3:30PM CDT
--Royalty revenues of $8.1 million, an increase of $2.6 million (47%) from third quarter 2013.

Furiex Pharmaceuticals Confirms Takeda's Submission of a New Drug Application for Trelagliptin Succinate (SYR-472) in Japan for the Treatment of Type 2 Diabetes
Business Wire - Fri Mar 07, 11:21AM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate (SYR-472), a once weekly dosage treatment for type 2 diabetes.

Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company") (NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes") in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing.

3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...

Bull of the Day: Endocyte (ECYT) - Bull of the Day
Kevin Cook - ZACKS - Wed Feb 12, 4:03AM CST
Bull of the Day: Endocyte (ECYT) - Bull of the Day

Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...

Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release and Conference Call
Business Wire - Mon Feb 10, 3:10PM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter 2013 financial results on Tuesday, March 11, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.

This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the  SPDR S&P Biotech Index  up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...

3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 08, 8:00AM CST
Seattle Seahawks fans are no doubt still celebrating their team's big victory in the Super Bowl last Sunday. But they're not the only ones with reason to be cheerful. Several health-care stocks enjoyed humongous gains this week. Great clinical...

Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

3 Stocks Breaking Out on Unusual Volume
at The Street - Thu Feb 06, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.

Furiex Soars on Positive Eluxadoline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 1:29PM CST
Shares of Furiex more than doubled on Feb 4 to close the trading session at $105.69.

Company news for February 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:06AM CST
Companies in the News are: FURX,MSFT,ATMI,PSTI

Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:04AM CST
Furiex Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by nearly 130% on the day.

Why Furiex Pharmaceuticals Inc. Is an Instant Double
David Williamson, The Motley Fool - Motley Fool - Tue Feb 04, 5:27PM CST
Shares of Furiex Pharmaceuticals exploded today, up 145% as the company released data that its drug treating a form of IBS that results in diarrhea passed its phase 3 trials, soundly beating a placebo at the higher dosing. In this video, Motley...

Nasdaq stocks posting largest volume increases
AP - Tue Feb 04, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Nasdaq stocks posting largest percentage increases
AP - Tue Feb 04, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Jim Cramer's 6 Stocks in 60 Seconds: DIS PFE AAPL SBUX TTWO FURX (Update 1)
at The Street - Tue Feb 04, 4:30PM CST
Cramer likes the call on Disney, sees good things happening for Pfizer but is staying away from Furiex Pharmaceuticals.

Why Furiex Pharmaceuticals, Lionbridge Technologies, and ATMI Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 04, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. It was another day of generally poor economic data, but...

Furiex Pharmaceuticals (FURX) Stock Research Links

FURX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 243

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 183

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 105

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 315

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 113

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 234

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 108

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 223

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading

Top 5 Most Recently Viewed Articles

20th Driskell Prize Gala: Celebrating African American Art

Updated Category News Views 306

The 20th Anniversary of the Driskell Prize Gala The David C. Driskell Prize Gala, often referred to as the "Met Gala of the South," is an extraordinary annual event that grandly honors the recipient of the Driskell Prize in African American Art and Art History. This prize holds the distinguished title of being the first national award recognizing the invaluable...

Continue Reading
Smartsheet Welcomes Eva Schoenleitner as New VP of Partner

Updated Category News Views 273

Smartsheet Strengthens Leadership with New Vice President Smartsheet, a leader in enterprise-grade work management, has made a significant decision in appointing Eva Schoenleitner as their Vice President of Partner. This move highlights the company’s focus on reinforcing their partner ecosystem and driving further growth in the tech industry. Experience That Counts...

Continue Reading
Piedmont Heart Institute Achieves New Heights in Transplants

Updated Category News Views 250

Piedmont Heart Institute Sets New Transplant Record Piedmont Heart Institute recently demonstrated its commitment to advancing cardiac care by achieving a remarkable milestone. In the year 2024, the institute performed 103 heart transplants at Piedmont Atlanta Hospital, establishing a new organizational record. This significant accomplishment underscores the institute's...

Continue Reading
Arizona Metals Corp's Promising Future at Kay Mine Project

Updated Category News Views 222

Arizona Metals Corp Unveils New Mineral Resource Estimate Arizona Metals Corp (TSX: AMC, OTC: AZMCF) has made waves in the mining sector with the recent announcement of its inaugural Mineral Resource Estimate (MRE) for the Kay Mine Project. This project signifies a significant milestone for the company, highlighting its resources and potential for growth. Insights into...

Continue Reading
Leidos Holdings, Inc. Raises Quarterly Cash Dividend Announcement

Updated Category News Views 147

Leidos Holdings, Inc. Announces Increased Dividend Leidos Holdings, Inc. (NYSE: LDOS) has made an exciting announcement regarding its quarterly cash dividend. The company’s board of directors has confirmed a quarterly cash dividend of $0.43 for each outstanding share of its common stock. This marks an increase of $0.03 from the previous dividend of $0.40 per share,...

Continue Reading